Inter- and intra-observer reproducibility of ADC measurements in esophageal carcinoma primary tumors

Abstract

The apparent diffuse coefficient (ADC) may correlate with the treatment response to chemotherapy/radiotherapy in solid tumors. Our aim was to determine the inter- and intra-observer reproducibility of ADC measurements in primary esophageal squamous cell carcinoma (ESCC). ADCs were blindly measured in 31 patients diagnosed with ESCC by two observers before treatment (pre-ADC) and after 5th fraction radiotherapy (intra-ADC) twice with a 2-week interval. The mean pre-ADC of primary tumors was 1.25±0.22 and 1.27±0.23 (in 10−3mm2/s) from observer A for measurements 1 and 2, respectively, and the intra-observer measurements were -0.02 bias vs. -0.13-0.09 limits of agreement. From observer B, the mean pre-ADC varied between 1.25±0.23 and 1.27±0.23 (in 10−3mm2/s) for measurements 1 and 2, respectively, and intra-observer measurements were -0.02 bias vs. -0.17∼0.16 limits of agreement. The mean pre-ADC of primary tumors was 1.26±0.24 (in 10−3mm2/s) from observers A and B, and inter-observer measurements were 0.01 bias vs. -0.09-0.09 limits of agreement, revealing a low inter-observer variance. Similar measurements of the intra-SD parameters showed that the pre- and intra-ADC of primary tumors differed significantly. Thus ADC measurements may have sufficient inter-observer and intra-observer reproducibility to measure primary tumor responses to treatment, and the ADCs before and during treatment differed.

Diffusion-Weighted MRI in Patients with Testicular Tumors—Intra- and Interobserver Variability

“…However, it is of great importance that the ADC measurements have a reproduceble interobserver variability [ 14 ]. Other studies with focus on ROI shape, ROI placement, and ADC measurements in various organs have good observer reproducibility [ 26 , 27 , 28 , 29 , 30 ].…”

A nanomicelle with miR-34a and doxorubicin reverses the drug resistance of cisplatin in esophageal carcinoma cells by inhibiting SIRT1 signal pathway

“…Chemotherapy is the first choice for the treatment of EC ( 22 ). However, many factors may impact the therapeutic effects of chemotherapy drugs, such as the p53 background and the efficiency of drug delivery ( 23 ). It is thus necessary to innovate different strategies to overcome these challenges.…”